Efficacy of acetaminophen in skin B16-F0 melanoma tumor-bearing C57BL/6 mice

International Journal of Oncology

Volumn 35, Issue 1, 2009, Pages 193-204

  Vad, Nikhil M ^a   Kudugunti, Shashi K ^a   Graber, Daniel ^a   Bailey, Nathan ^a   Srivenugopal, Kalkunte ^a   Moridani, Majid Y ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Acetaminophen; C32; C57BL 6 mice; Melanoma; MeWo; Phenacetin; Short hairpin RNA; SK MEL 24; SK MEL 28; SK MEL 5; Tyrosinase

Indexed keywords

GLUTATHIONE; MONOPHENOL MONOOXYGENASE; PARACETAMOL; REACTIVE OXYGEN METABOLITE; SHORT HAIRPIN RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SIZE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SELECTIVITY; ENZYME ACTIVITY; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY PARENCHYMA; LIPID PEROXIDATION; LIVER PARENCHYMA; MALE; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; OXIDATIVE STRESS; PLASMID; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION;

ACETAMINOPHEN; ANIMALS; ANTINEOPLASTIC AGENTS; ASCORBIC ACID; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUTATHIONE; HUMANS; INHIBITORY CONCENTRATION 50; KIDNEY; LIPID PEROXIDATION; LIVER; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MONOPHENOL MONOOXYGENASE; NAD; OXIDATION-REDUCTION; PHENACETIN; REACTIVE OXYGEN SPECIES; RNA INTERFERENCE; SKIN NEOPLASMS; SULFHYDRYL COMPOUNDS; TIME FACTORS;

EID: 67649448802     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000329     Document Type: Article

References (32)

1. Lens MB and Dawes M: Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol 150: 179-185, 2004.
2. Garbe C, McLeod GR and Buettner PG: Time trends of cutaneous melanoma in Queensland, Australia and Central Europe. Cancer 89: 1269-1278, 2000.
3. Diepgen TL and Mahler V: The epidemiology of skin cancer. Br J Dermatol 146 (Suppl 61): 1-6, 2002.
4. Naish S, Cooksey CJ and Riley PA: Initial mushroom tyrosinase-catalysed oxidation product of 4-hydroxyanisole is 4-methoxy-ortho-benzoquinone. Pigment Cell Res 1: 379-381, 1988.
5. Naish S, Holden JL, Cooksey CJ and Riley PA: Major primary cytotoxic product of 4-hydroxyanisole oxidation by mushroom tyrosinase is 4-methoxy ortho benzoquinone. Pigment Cell Res 1: 382-385, 1988.
6. Moridani MY, Cheon SS, Khan S and O'Brien PJ: Metabolic activation of 4-hydroxyanisole by isolated rat hepatocytes. Drug Metab Dispos 30: 1063-1069, 2002.
7. Riley PA, Cooksey CJ, Johnson CI, Land EJ, Latter AM and Ramsden CA: Melanogenesis-targeted anti-melanoma pro-drug development: Effect of side-chain variations on the cytotoxicity of tyrosinase-generated ortho-quinones in a model screening system. Eur J Cancer 33: 135-143, 1997.
8. Riley PA: Hydroxyanisole depigmentation: In-vitro studies. J Pathol 97: 193-206, 1969.
9. Vad NM, Yount G, Moore D, Weidanz J and Moridani MY: Biochemical mechanism of acetaminophen (APAP) induced toxicity in melanoma cell lines. J Pharm Sci 98: 1409-1425, 2009.
10. Moridani MY, Moore M, Bartsch RA, Yang Y and Heibati-Sadati S: Structural toxicity relationship of 4-alkoxyphenols' cytotoxicity towards murine B16-F0 melanoma cell line. J Pharm Pharm Sci 8: 348-360, 2005.
11. Vad NM, Yount G and Moridani MY: Biochemical mechanism of acetylsalicylic acid (aspirin®) selective toxicity towards melanoma cell lines. Melanoma Res 18: 386-399, 2008.
12. Wu X, Zeng H, Zhang X, et al: Phosphatase of regenerating liver-3 promotes motility and metastasis of mouse melanoma cells. Am J Pathol 164: 2039-2054, 2004.
13. Moridani MY, Cheon SS, Khan S and O'Brien PJ: Metabolic activation of 3-hydroxyanisole by isolated rat hepatocytes. Chem Biol Interact 142: 317-333, 2003.
14. Vad NM, Shaik IH, Mehvar R and Moridani MY: Metabolic bioactivation and toxicity of ethyl 4-hydroxy benzoate in human SK-MEL-28 melanoma cells. J Pharm Sci 97: 1934-1945, 2008.
15. Shaik IH and Mehvar R: Rapid determination of reduced and oxidized glutathione levels using a new thiol-masking reagent and the enzymatic recycling method: Application to the rat liver and bile samples. Anal Bioanal Chem 385: 105-113, 2006.
16. Siraki AG, Chan TS and O'Brien PJ: Application of quantitative structure-toxicity relationships for the comparison of the cytotoxicity of 14 p-benzoquinone congeners in primary cultured rat hepatocytes versus PC12 cells. Toxicol Sci 81: 148-159, 2004.
17. Johansen IE: Intron insertion facilitates amplification of cloned virus cDNA in Escherichia coli while biological activity is reestablished after transcription in vivo. Proc Natl Acad Sci USA 93: 12400-12405, 1996.
18. Gergel' D and Cederbaum AI: Interaction of nitric oxide with 2-thio-5-nitrobenzoic acid: Implications for the determination of free sulfhydryl groups by ellman's reagent. Arch Biochem Biophys 347: 282-288, 1997.
19. Ellman GL: Tissue sulfhydryl groups. Arch Biochem Biophys 82: 70-77, 1959.
20. Wills ED: Mechanisms of lipid peroxide formation in animal tissues. Biochem J 99: 667-676, 1966.
21. Kaur G, Tirkey N, Bharrhan S, Chanana V, Rishi P and Chopra K: Inhibition of oxidative stress and cytokine activity by curcumin in amelioration of endotoxin-induced experimental hepatoxicity in rodents. Clin Exp Immunol 145: 313-321, 2006.
22. Sedlak J and Lindsay RH: Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal Biochem 25: 192-205, 1968.
23. Kawai S, Yoshinari M, Matsumoto J, Kirinoki M, Aikawa M, Minami M and Matsuda H: Plasmodium coatneyi-infected erythrocytes bind to C32 amelanotic melanoma cells under static and flow conditions. J Vet Med Sci 65: 375-380, 2003.
24. Hirosaki K, Yamashita T, Wada I, Jin HY and Jimbow K: Tyrosinase and tyrosinase-related protein 1 require Rab7 for their intracellular transport. J Invest Dermatol 119: 475-480, 2002.
25. Naish-Byfield S, Cooksey CJ, Latter AM, Johnson CI and Riley PA: In vitro assessment of the structure-activity relationship of tyrosinase-dependent cytotoxicity of a series of substituted phenols. Melanoma Res 1: 273-287, 1991.
26. Simonova M, Wall A, Weissleder R and Bogdanov A Jr: Tyrosinase mutants are capable of prodrug activation in transfected nonmelanotic cells. Cancer Res 60: 6656-6662, 2000.
27. Picardo M, Passi S, Nazzaro-Porro M, Breathnach AS, Zompetta C, Faggioni A and Riley P: Mechanism of antitumoral activity of catechols in culture. Biochem Pharmacol 36: 417-425, 1987.
28. Rossi JJ: Expression strategies for short hairpin RNA interference triggers. Hum Gene Ther 19: 313-317, 2008.
29. Chen YM and Chavin W: Tyrosinase activity in highly pigmented human melanoma and in negro skin. Proc Soc Exp Biol Med 145: 695-698, 1974.
30. Roberts LJ II and Morrow JD: Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout. In: The Pharmacological Basis of Therapeutics. Hardman JG, Limbird LE and Gilman AG (eds). McGraw-Hill, New York, pp687-692, 2001.
31. Savides MC and Oehme FW: Acetaminophen and its toxicity. J Appl Toxicol 3: 96-111, 1983.
32. Wolchok JD, Williams L, Pinto JT, et al: Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma. Melanoma Res 13: 189-196, 2003.